MedicaidPrior AuthLow impact
Beleodaq® (belinostat) (New)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established a new prior authorization policy for Beleodaq (belinostat), an IV cancer medication used for relapsed/refractory peripheral T-cell lymphoma. The policy requires prior authorization with specific criteria including diagnosis confirmation and exclusions for disease progression or concomitant therapies.
Action Required
Before January 1, 2026: Billing and clinical teams must implement prior authorization requirements for Beleodaq (belinostat) IV infusions for Louisiana Medicaid patients. Update billing workflows to verify patient diagnosis of relapsed/refractory PTCL and confirm no exclusion criteria before treatment. Submit prior authorization requests through www.humana.com/PAL. Claims will be denied without proper authorization.